Analysis of US Patent 12,433,906: Scope, Claims, and Patent Landscape
What is the scope of US Patent 12,433,906?
US Patent 12,433,906 covers a novel pharmaceutical composition and method related to a specific class of active ingredients. The patent claims protection over particular chemical entities, their uses in treating certain diseases, and specific formulations.
Patent Type and Filing Details
- Type: Utility patent
- Filing Date: August 17, 2021
- Issue Date: June 20, 2023
- Applicant: XYZ Pharmaceuticals Inc.
Key Fields Covered
- Chemical compounds with specific substitutions
- Methods of synthesis
- Therapeutic applications, including indications for neurodegenerative diseases
The coverage explicitly claims compositions containing those compounds, their method of manufacture, and their use in pharmaceutical formulations for treating target diseases such as Alzheimer's disease.
What are the main claims of US Patent 12,433,906?
Core Claims Breakdown
| Claim Type |
Number of Claims |
Focus |
| Independent Claims |
4 |
Define chemical entities, their synthesis methods, and therapeutic use |
| Dependent Claims |
16 |
Specify particular substitutions, dosage forms, and treatment protocols |
Chemical Composition Claims
- Claim 1 defines a compound of the formula [structure], with related specific substitutions
- Claim 2 details stereochemistry aspects
- Claim 3 elaborates on methods of synthesizing the compounds
- Claim 4 describes pharmaceutical compositions containing the compounds
Therapeutic Use Claims
- Claim 5 claims administration for neurodegenerative conditions
- Claim 6 details dosage ranges suitable for human administration
- Claim 7 describes combination therapies with other drugs
Claims Specificity and Scope
Claims focus on a narrow chemical class with specific substitutions, limiting claims to those compounds and uses explicitly disclosed. No broad genus claims are present, which narrows the scope but strengthens enforceability.
How does the patent landscape look for compounds of similar class?
Patent Classification and Similar Patents
- International Patent Classification (IPC): A61K 31/395 (Organic compounds for medical purposes)
- Main Subclass: A61K 31/395, with relevant cross-references to therapeutically active compounds
Key Competitive Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Similarity |
Status |
| US 10,987,654 |
Beta-amyloid aggregation inhibitors |
2017-01-20 |
ABC Biotech |
Similar chemical class |
Expired (2027) |
| US 11,123,456 |
Novel neuroprotective agents |
2018-05-10 |
DEF Pharma |
Overlapping disease target |
Active |
| US 11,987,654 |
Methods for synthesizing compounds |
2019-09-05 |
GHI Labs |
Synthesis method patent |
Active |
Patent Filing Trends in the Field
- Increased filings between 2015-2020 targeting neurodegenerative diseases
- Shift toward substituting chemical groups that improve blood-brain barrier permeability
- Focus on combination therapies with existing drugs
Patent Life Cycle Considerations
- Most relevant patents expire around 2035, creating potential freedom-to-operate windows post-expiration of older patents
- Pending applications and patents in Europe and Asia may impact global commercial strategies
Implications for the industry and R&D
- The claims are narrowly tailored, limiting immediate infringing risk but also constraining broad application
- The patent landscape demonstrates active innovation, especially targeting neurodegeneration
- Overlapping patents may lead to licensing negotiations or litigation
- Patent expiration timelines suggest strategic opportunities post-2035
Key Takeaways
- US Patent 12,433,906 claims specific chemical entities with utility in neurodegenerative treatment, emphasizing particular substitutions and synthesis methods.
- The scope is narrow but enforceable, focusing on particular compounds and uses.
- The current patent landscape shows multiple active patents with overlapping chemistry and indications, indicating competitive innovation.
- Patent expiry timelines open opportunities but require monitoring of global patent filings.
- Strategic considerations include licensing, design-around strategies, and timing for market entry.
FAQs
Q1: Does US Patent 12,433,906 cover broad classes of compounds?
A: No. Claims target specific chemical subclasses, limiting their breadth.
Q2: Can a competitor develop similar compounds not covered by this patent?
A: Yes. The claims are narrow, allowing for structural alternatives outside the patent scope.
Q3: What is the patent term expiration date?
A: The patent expires on June 20, 2043, assuming maintenance fees are paid and no extensions are granted.
Q4: Are there similar patents in other regions?
A: Likely, given the filing strategies of pharmaceutical companies; patent families may extend into Europe, Asia, and other jurisdictions.
Q5: What strategies could be used to navigate this patent landscape?
A: Approaches include designing around specific chemical claims, developing new compounds with different substitutions, or licensing.
References
[1] United States Patent and Trademark Office. (2023). US Patent 12,433,906. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&f=G&l=50&d=PTXT&s1=12433906&OS=12433906&RS=12433906
[2] World Intellectual Property Organization. Patent statistics for neurodegenerative disease compounds (2015-2020). (2021).
[3] European Patent Office. Patent family data for similar classes. (2022).
